Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)
Phase III Clinical Trial Evaluating the Efficacy of 5-aminolevulinic Acid (5-ALA HCl) Fluorescence-guided Microsurgery Versus Conventional White Light Microsurgical Resection in Patients With Malignant Gliomas (WHO Grade 3/4)
Sponsor: Lee's Pharmaceutical Limited
A PHASE3 clinical study on 5-aminolevulinic Acid and Fluorescence-guided Resection, this trial is actively recruiting participants. The trial is conducted by Lee's Pharmaceutical Limited and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lee's Pharmaceutical Limited
For direct contact, visit the study record on ClinicalTrials.gov .